226 related articles for article (PubMed ID: 27318265)
1. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.
Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
Urology; 2016 Oct; 96():171-176. PubMed ID: 27318265
[TBL] [Abstract][Full Text] [Related]
2. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
3. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
[TBL] [Abstract][Full Text] [Related]
4. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
5. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
6. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2016 Dec; 122(24):3848-3855. PubMed ID: 27505036
[TBL] [Abstract][Full Text] [Related]
7. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
8. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
[TBL] [Abstract][Full Text] [Related]
9. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
[TBL] [Abstract][Full Text] [Related]
10. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
Bonde TM; Westerberg M; Aly M; Eklund M; Adolfsson J; Bill-Axelson A; Garmo H; Stattin P; Robinson D
Scand J Urol; 2022 Jun; 56(3):169-175. PubMed ID: 35548951
[No Abstract] [Full Text] [Related]
11. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
13. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Pratson CL; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):333-7. PubMed ID: 26171882
[TBL] [Abstract][Full Text] [Related]
14. Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer-A Systematic Literature Review and Pooling of Individual Participant Data.
Aly M; Hashim M; Heeg B; Liwing J; Leval A; Mehra M; Lawson J; Brookman-May SD; Akre O
Eur Urol Focus; 2019 Sep; 5(5):788-798. PubMed ID: 29627197
[TBL] [Abstract][Full Text] [Related]
15. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
Miyoshi Y; Ohtaka M; Kawahara T; Ohtake S; Yasui M; Uemura K; Yoneyama S; Yokomizo Y; Uemura H; Miyamoto H; Yao M
Urol Int; 2019; 102(1):37-42. PubMed ID: 30326476
[TBL] [Abstract][Full Text] [Related]
17. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
Mithal P; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Kane CJ; Amling C; Freedland SJ
BJU Int; 2016 Feb; 117(2):244-8. PubMed ID: 26010160
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
[TBL] [Abstract][Full Text] [Related]
19. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
Sourbeer KN; Howard LE; Moreira DM; Amarasekara HS; Chow LD; Cockrell DC; Hanyok BT; Pratson CL; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Hernandez RK; Freedland SJ
J Urol; 2015 Apr; 193(4):1232-8. PubMed ID: 25463986
[TBL] [Abstract][Full Text] [Related]
20. Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.
Kuo KF; Hunter-Merrill R; Gulati R; Hall SP; Gambol TE; Higano CS; Yu EY
Clin Genitourin Cancer; 2015 Feb; 13(1):10-6. PubMed ID: 25242417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
